Rachel K. Voss, M.D., M.P.H., Jane C. Lin, M.S., Michelle T. Roper, M.D. Mohammed H. Al-Temimi, M.D., Joseph Ruan, M.D., Warren Tseng, M.D., Michael Tam, M.D., Matthew J. Sherman, M.D., Daniel D. Klaristenfeld, M.D., Marco J. Tomassi, M.D.
April 2020, Volume 63, Issue 4;
In stage 2/3 rectal cancer treated with chemoradiotherapy and surgery, the addition of adjuvant chemotherapy was not associated with decreased recurrence-free survival in the entire cohort or in any subgroup, whereas tumor response to chemoradiotherapy is closely associated with disease recurrence. These findings have important consequences for treatment and surveillance decisions for patients with rectal cancer. Presurgical efforts that maximize tumor downstaging, such as total neoadjuvant therapy, may produce better oncologic outcomes than traditional adjuvant chemotherapy.